https://www.selleckchem.com/pr....oducts/bms303141.htm
Both observational studies investigated all kinds of patients with initial RASi treatment. In patients with RASi, the EWKF group had a higher risk of all-cause mortality than the no-EWKF group in the randomized studies (n= 13 581; RR, 1.22; 95% CI, 1.04-1.42; P=.02) and in observational studies (n=148 144; OR, 1.70; 95% CI, 1.43-2.01; P .00001). In patients who experienced EWKF, no statistically significant difference was found between the efficacy of RASi and placebo in all-cause mortality (n=1762; RR, 0.85; 95% CI, 0.68-1.06; P
Like
Comment
Share
